for moderate-risk RR2378 ($75) for all ages. Average reimbursement rate was RR2,000 ($63) per outpatient episode. The average cost of hospitalization was RR20,870 ($655/ n= 500), RR20,925 ($657/n= 125) for low-risk, RR20,947 ($657/n= 364) for moderaterisk, and RR17,684 ($554/n= 11) for high-risk patients; with 60%-80% of patients with CAP hospitalized and the estimated number of CAP patients of age 50 and older in Tver 3,249, the annual cost of CAP to payer is RR53,448,423 (~$1.7million); the national estimates of cost of CAP in senior adults was $124million. Employed patients comprise 12.8% and 18.3% among the inpatient and outpatient cases, respectively, and days lost from work per employed patient was 8.0 (inpatient) and 7.0 (outpatient). ConClusions: CAP in adults is a significant cause of resource use and health care cost in Russia, inpatient care constitutes the majority of cost. Cost of treatment was similar across all age and risk groups. objeCtives: The aim of this study is to investigate the medical costs of COPD patients in South Korea. Methods: We enrolled 300 COPD patients who had been treated and followed up for more than one year in the three hospitals from 2012 to 2013. The hospital electronic database was used to obtain medical costs and the medical records were reviewed by physicians (respiratory specialists) to assess clinical characteristics. We calculated annual maintenance costs per-patient according to disease severity, except the costs which were related to COPD exacerbation. The costs of COPD exacerbation per-case was calculated and divided into severe-exacerbation (hospitalization and emergency visit) costs and non-severe-exacerbation (outpatient visit) costs. Results: The annual maintenance costs per-patient was KRW 351,599, KRW 401,068, KRW 573,010 and KRW 999,506 for mild, moderate, severe and very-severe according to GOLD criterion, respectively. In case of the COPD exacerbation, the costs per-case for each non-severe exacerbation and severeexacerbation was KRW 163,495 and KRW 2,765,086. ConClusions: The severity of disease and exacerbation of COPD have a substantial impact on the medical costs of COPD patients. Improvement of lung function and reduction of occurrence of COPD exacerbation will be beneficial for the reduction of the health care expenditures.
objeCtives: Asthma is one of the mostly seen chronic illnesses in Turkey, yet there are limited studies on cost of asthma in our country. In addition they were based on a central database and weight of disease. The aim of this study was estimating the nationwide cost of managing asthma and examining its variability depending on asthma control level. Methods: The clinical pathway for asthma was determined from the literature. Part of the data was collected from the expert's clinical view. To calculate the direct costs, the medical management of adult asthma was estimated using 'cost-of-illness' methodology for one year per patient. All costs were calculated according to payer perspective. The costs covered were pyhsician visits, hospitalizations, diagnostic tests, medicine and comorbid disease. Results: According to recent studies, the percentage of controlled, partially controlled and uncontrolled patients were 22%, 50%, and %28 respectively in Turkey. The cost of asthma calculation was based on weighted percentage of control. The mean annual cost per patient with controlled asthma was € 558,41, partially controlled asthma was € 594,86 and uncontrolled asthma was € 1040,63. Hospitalizations, physician visits, diagnostic tests, comorbidity and medication costs were estimated to be 4%, 11%, 11%, 28%, 46% for controlled patient, 10%, 11%, 10%, 43%, 26% for partially controlled patient and 48%, 6%, 6%, 25%, 15% for uncontrolled patient respectively. ConClusions: The cost of adult asthma in Turkey is very high and it significantly depends on disease control level. As expected, uncontrolled patient's cost is higher than that of controlled patient. Nationwide health policies such as education of patients and physicians, selecting the right treatment and smoking cessation strategies that target the effective control of asthma will play an important role in the reduction of the economic burden of disease. objeCtives: COPD is one of the leading causes of morbidity and mortality worldwide and has a major burden on Russian's health care system. It's lead to frequent use of health care resources. The main aim of this study was to describe the direct costs for management of COPD patients with differing degrees of disease severity. Methods: The methodology for cost of illness analysis was based on a previous Russian study (Avksenteva M. V. et al., 2010) . One-year costs were identified by applying cost data to medical information obtained by medical statistical records from 2007. In this study were performed 2 variants of COPD costs. In 1 st variant were used epidemiological data from 2007 and medical resources costs from 2014. In 2 nd variant were used extrapolated epidemiological data and medical resources costs from 2014. Due to lack of actual data in this study was modeled situation -from 2007 to 2012 the overall incidence of adult increased by 12.5%. Medical resources included hospital stays, outpatient visits and ambulance service. Results: The mean annual overall direct health care cost for 1 st variant was estimated to be 54.6 billion rubles ($1.6 billion), for 2 nd variant was estimated to be 61.6 billion rubles ($1.8 billion objeCtives: Asthma is the most common chronic disease in childhood, reduces the quality of life of children and their families, and produces high social and health care costs. The aim of this study was to estimate the direct cost of pediatric asthma in Turkey and to examine its variability depending on asthma control level. Methods: The clinical pathway for childhood asthma was designed by and based on the data from the available Turkish literature. Unavailable data was collected by the expert's clinical view. To calculate direct costs, the medical management of childhood asthma estimated using 'cost-of-illness' methodology for one year per child. All costs were calculated from the health care payer perspective. The costs were covered hospitalizations, physician visits, diagnostic tests, medications and co morbid diseases. Results: According to the recent studies, the controlled patient was 60%, partial controlled patient was 25%, and uncontrolled patient was 15% in Turkey. The cost of asthma calculation was based on weight of control. The mean annual cost per patient with controlled asthma is 542.97€ , partial controlled asthma 714.52€ and uncontrolled asthma 1047.86€ . Hospitalizations, physician visits, diagnostic tests, co morbid diseases costs and medication costs estimated 4 %, 21%, 7%, 27%, 40% of total costs for controlled patient, 27%, 16%, 5%, 21%, 31% of total costs for partial controlled patient and 50%, 11%, 4%, 14%, 21% for uncontrolled patient respectively. ConClusions: The direct cost of pediatric asthma in Turkey increases depending on disease control level along with different spectrum of item distributions. To increase the utility and effectiveness of health care system, the findings of this evaluation may guide to construct future policies. objeCtives: Pulmonary arterial hypertension (PAH) is a rare disease, for which only scarce health care cost data is available in Europe. The progressive nature of the disease often requires hospitalization, the costs of which are currently unknown in Belgium, mainly due to the low number of patients affected. The objective of this research was to assess the cost and length of stay (LOS) of a PAH-related hospitalization likely related to disease worsening in Belgium. Methods: A retrospective database analysis was performed using the IMS hospital disease database from 2009 to 2011, covering 20% (2010/2011) to 34% (2009) of the hospital beds in Belgium. Data on adult patients, who were either hospitalized with a primary diagnosis of primary pulmonary hypertension (PH) (ICD-9-CM code 416.0) OR were receiving ≥ 1 medication indicated for PAH, was extracted. To ensure hospitalizations were likely related to disease worsening and not to planned procedures or routine visits, only unscheduled hospitalizations of at least 2 days were included in the analysis. Hospitalizations were excluded if primary co-diagnoses were suggestive of a non-PAH-related reason for the admission. Total hospitalization costs, including hotel, drugs, procedure costs (extrapolated to 2013), and length of stay (LOS) were analyzed with descriptive statistics. Results: 35 hospitalizations were included into the study. Patients experiencing these admissions were mainly female (71.4%), which is in line with the known female-male ratio (2-1) for this rare disease. Mean (SD) hospitalization cost was € 20,229 (9,399), including € 4,396 (9,502) drug, € 8,499 (8,999) hotel, and € 7,334 (12,386) procedure costs. Average LOS was 17.7±16.8 days. ConClusions: Long durations and high incurred costs for PAHrelated hospitalizations reveal the severe morbidity, health care, and patient burden of PAH in Belgium.
PRS33 econoMic buRden in diRecT coSTS of chRonic obSTRucTive PulMonaRy diSeaSe (coPd) in RuSSia

PRS29 coST of a PulMonaRy aRTeRial hyPeRTenSion-RelaTed hoSPiTalizaTion in belgiuM
PRS30
The coST buRden of coMMuniTy-acquiRed PneuMonia in RuSSia in adulTS of 50 and oldeR: a Regional STudy and naTional eSTiMaTeS objeCtives: Community-acquired pneumonia (CAP) represents a considerable burden in Russia. We assessed cost of CAP in Russia to characterize disease burden in Russian adults of age 50 and older. Methods: We conducted a retrospective chart review in a central Russian region of Tver for samples of 900 patients treated in inpatient and outpatient settings, and extrapolated data nationally. All patients were 50 years of age and represented new cases of CAP. Data were collected on demographics, comorbidities, and employment. The cost was estimated from the public payer perspective, with a productivity loss in patients below retirement age. Results: Cost of treatment was similar across age-and-risk groups in hospital and in outpatient settings. The cost of an outpatient episode was estimated far all risk groups at RR2176 ($69), ranging from RR1,939 ($61) to RR2537 (~$80) for age groups 50-64 and 75-84 respectively; the cost of episode for low-risk patients was RR1737 ($55), and culated. Methods: The costs including lab investigation charges, unit costs of treatment per bed, medication charges, food costs, transportation costs and loss of productivity were calculated per asthma episode. Data was analysed by Statistical Package for the Social Sciences (SPSS) version 18.0 using various descriptive and inferential statistical tests. Results: A median medical cost of acute exacerbation of asthma under Ministry of Health's (MOH) perspective was USD 105.00 (RM338.47) per episode. Medication cost comprised the majority (52.38%) of the total medical costs. A median medical cost of acute exacerbation of asthma under patient's perspective was USD 1.55 (RM4.99) per episode. ConClusions: Asthma exacerbation and length of stay in the hospital were proportional to the direct medical costs. In Malaysia, a substantial proportion of the direct medical cost of asthma treatment is heavily subsidised for the locals.
PRS38 PhaRMacoeconoMic evaluaTion and buRden of illneSS of acuTe exaceRbaTion of coPd in PaTienTS in MalaySia
objeCtives: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) appears to be the main reason of hospitalization in COPD patients. Since substantial economic burden of COPD have not been previously studied in Malaysia, this study aimed at estimating and identifying different costs and related burden of illness in patients receiving treatment of AECOPD in a tertiary care hospital in Malaysia. Methods: A prospective follow-up study was performed in Department of Accident and Emergency and Respiratory Medicine of the hospital. Data were derived on the basis of per exacerbation episode. Relationship between direct medical costs and disease severity was analyzed using various descriptive and inferential statistical approaches. Results: Median actual direct medical costs and out-ofpocket costs were RM 457.68 (US$ 141.97) and RM 28.25 (US$ 8.76) per exacerbation respectively. Drug cost (41%) was the leading cost driver, followed by unit cost of treatment per bed (33.6%) and lab investigation cost (25.4%). However, food cost (44.2%) represented the largest proportion in out-of-pocket costs. More than 90% of actual direct medical costs were supported by the Government of Malaysia in the patients studied. ConClusions: Impacts of AECOPD in health care resources are worthy of attention. Cost information from pharmacoeconomic studies is important in decision making for health care professionals and policy makers in order to improve health care outcome and minimize costs.
PRS39 PRoSPecTive STudy on The aveRage coST of TheRaPy foR bRonchial aSThMa PaTienTS in an indian TeRTiaRy caRe Teaching hoSPiTal
Nair S. V. , Abdulsalim S. , Yedavalli N. S. , Shukla R. , Mohan M. K. Manipal University, Manipal, India objeCtives: To conduct a study to determine the average cost of therapy for bronchial asthma patients in a tertiary care center. Methods: A prospective observational study was carried out on a 100 bronchial asthma patients after ethical clearance was obtained from an Independent Ethical Review (IEC) board. The patients selected for the study were in-patients admitted to the Medicine and Pulmonary wards for bronchial asthma related complaints with and without co-morbidities. The study assessed the average cost of therapy which was obtained from patient records. Statistical analysis was performed using SPSS version 20. Results: The mean age of the study population (N= 100) was 53.30±14.59. Females constituted 61% of the study population. The job profiles of the majority of study population were house wives (53%) and agriculturist (15%). The average cost of therapy among 100 patients was found to range from $1.81 to $598. The impact on the length of stay on cost of therapy per day was classified into ≤ 5, 6-10, 11-21 days and cost was found to be $9.21 ± 5.57, $12.12 ±9.65 and $15.56±10.36 respectively. Impact of co-morbidities (35%) and without co-morbidities on cost of therapy per day was found to be $13.03 ± 10.63 and $8.54 ± 6.77 respectively. ConClusions: Asthma creates a substantial financial burden on the society and results in compromise on diagnosis and treatment mainly in a developing country like India. There was a substantial increase in the cost of therapy as the duration of hospital stay increased and also in the case of patients with co-morbidities. Pharmacoeconomic analysis is needed to develop strategies to reduce the cost of therapy and thereby achieve greater medication adherence and improved quality of life in asthma patients.
PRS40
ReSouRce uSe and healTh caRe coSTS of chRonic obSTRucTive PulMonaRy diSeaSe in SlovaKia Ondrusova M. , Psenkova M. , Mackovicova S. Pharm-In Ltd, Bratislava, Slovak Republic objeCtives: The objective of this cost study was to measure the resource utilisation and the direct costs associated with health care management of patients with chronic obstructive pulmonary disease (COPD) in Slovakia and to provide a basis for cost-effectiveness evaluations. Methods: The cross-sectional survey was performed to obtain the information on the management of patients with COPD and to estimate the direct costs of the disease management. The survey included 4 experts experienced in COPD treatment. The studied population were cohorts of COPD patients evaluated separately according to the stage of the disease (mild, moderate, severe and very severe). The patients were treated with standard therapy, the cost were set for one average patient per 3 months of treatment. The cost data were assessed and actualized due the 1st July 2014. All types of health care used in COPD management were evaluated (hospitalization, outpatient visits, diagnostics, laboratory tests and the management of symptoms, use of bronchodilators). Moderate structure of direct costs in Russia was as follows -77% for hospital stays, 21% for outpatient visits, 2% for ambulance service. COPD exacerbations contributed the major portion of cost and also correlated with disease severity. ConClusions: COPD associated with significant economic burden on Russian's health care system. There is a striking direct relationship between the cost of care and severity of the disease with hospitalization leading to disease exacerbation being a major portion of cost. Medicine, Seoul, South Korea, , 2 Chung-Ang University, Seoul, South Korea objeCtives: Atopic dermatitis is a global public health concern considering its growing prevalence and mounting socioeconomic burden. However, Few studies has assessed the economic impact of atopic dermatitis in Korea. To conduct a cost analysis of atopic dermatitis and evaluate the economic impact of the disease on individual annual disease burden, quality of life, and change in medical expenses in regards to change in health related quality of life. Methods: This prospective cost analysis of atopic dermatitis by reviewing the housekeeping account books of 32 patients was conducted and evaluated the economic impact of the disease by analyzing the completed questionnaires. To handle the potential uncertainties, we compared the results with the data released by the Health Insurance Review & Assessment Board on medical costs claimed by the health care facilities. Results: In regards to the cost of illness, direct cost of atopic dermatitis per patient during the 3 month study period was 541,280 KRW and expenditure on other atopic dermatitis related products was 120,313 KRW. Extrapolated annual direct cost (including expenditures on other atopic dermatitis related product) per patient was 2,646,372 KRW. Estimated annual indirect cost was 1,507,068 KRW. Annual cost of illness of atopic dermatitis, computed by adding up direct and indirect costs, was estimated to be 4,153,440 KRW. ConClusions: The annual total social cost on a national level was estimated at 5.8000 trillion KRW.
PRS34 The coSTS of illneSS of aToPic deRMaTiTiS in SouTh KoRea
PRS35 The coST STudy of healTh SeRviceS in Mongolia
Damdinbazar O. Mongolian National University of Medical Science, Ulaanbatar, Mongolia objeCtives: There are three main funding sources of health system In Mongolia which are state budget, health insurance and out of pocket payment. Health insurance funded health care service based on 115 DRG and total financing to health care organizations were 87.1 billion MNT in 2011. Health insurance rates 240000 MNT secondary and thirtary level of hospital by the same tariff. Aim of the study is to calculate 10 DRG costs which were spent 25 percent of the health insurance fund in 2012. Methods: We used both top down and bottom-up cost allocation method. Secondary data were used. Results: Respiratory diseases finance is 9 percent higher than the real cost. Other 9 diagnostic groups finance were less than actual cost by 8-62%. That the total funding based on the number of cases nationwide, 12,032,906,381 MNT funding was insufficient. ConClusions: Health insurance base tariff have to change based on the study while base rates should be different at secondary and thirtary level of health care organization. objeCtives: To assess the direct and indirect medical costs incurred in the treatment of tuberculosis (TB) in patients attending public hospitals in Pakistan. Methods: A descriptive cross-sectional study was conducted in patients attending Accident and Emergency and TB wards of the hospitals in Pakistan by convenient-sampling technique. The direct and indirect medical costs were determined by various parameters like consultation fees, cost of medicines, travelling costs and laboratory test expenses etc. All obtained data were analyzed using descriptive and inferential statistics. Results: The mean annual direct medical cost for a TB patient was around Rs. 17317.56 (US$ 176.26) and indirect medical cost was Rs. 12918.50 (US$ 131.48). It was also observed that ccomparatively higher direct and indirect medical costs per patient (p < 0.001) were associated with large and urban hospitals. Besides, association of indirect medical costs with gender and age were the persuasive predictors of the study. ConClusions: Severity of the disease, distance to the hospital and length of stay in the hospital were proportional to the direct and indirect medical costs. In Pakistan, a significant proportion of the direct medical cost for TB treatment is subsidized for the public.
PRS36 a PhaRMacoeconoMic caRe analySiS of TubeRculoSiS conTRol in PaKiSTan
PRS37 PhaRMacoeconoMic evaluaTion of acuTe exaceRbaTion of aSThMa in PaTienTS in MalaySia
